期刊
BONE MARROW TRANSPLANTATION
卷 50, 期 4, 页码 476-482出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/bmt.2014.312
关键词
-
资金
- Gentium S.p.A
- Molmed S.p.A
- AstellasPharma Europe Ltd
- Celgene International SARL
- Clinigen Group Ltd
- Gilead Sciences Europe Ltd
- GlaxoSmithKline plc
- Hospira Inc.
- Medac Hematology GmbH
- MiltenyiBiotec GmbH
- MSD SharpDohme GmbH
- Neovii Biotech GmbH
- Sanofi Oncology
- Takeda
- Terumo BCT
- Therakos Photopheresis
- Alexion
- Amgen Oncology GmbH
- Exem Consulting SA
- Kiadispharma
- Macropharma
- Mundipharma
- Pierre Fabre Medicament SAS
A record number of 39 209 HSCT in 34 809 patients (14 950 allogeneic (43%) and 19 859 autologous (57%)) were reported by 658 centers in 48 countries to the 2013 survey. Trends include: more growth in allogeneic than in autologous HSCT, increasing use of sibling and unrelated donors and a pronounced increase in haploidentical family donors when compared with cord blood donors for those patients without a matched related or unrelated donor. Main indications were leukemias, 11 190 (32%; 96% allogeneic); lymphoid neoplasias, 19 958 (57%; 11% allogeneic); solid tumors, 1543 (4%; 4% allogeneic); and nonmalignant disorders, 1975 (6%; 91% allogeneic). In patients without a matched sibling or unrelated donor, alternative donors are used. Since 2010 there has been a marked increase of 96% in the number of transplants performed from haploidentical relatives (802 in 2010 to 1571 in 2013), whereas the number of unrelated cord blood transplants has slightly decreased (789 in 2010 to 666 in 2013). The use of donor type varies greatly throughout Europe.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据